Profusa targets $200-$250M revenue by 2030, EU Lumee oxygen launch in Q2 2026

Profusa, Inc.

EU Lumee tissue oxygen monitoring launch expected early Q2 2026 after CE marking late Q1 2026.
2026 revenue projected $0.5–$2M; 2027 revenue $9–$13M; 2030 revenue $200–$250M.
US oxygen launch planned for Q1 2027; EU glucose monitoring mid-2027.
Estimates 35% European population coverage through intended distribution channels.
Targets $10.5B tissue oxygen market and >500M glucose monitoring population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.